Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership
Shots:
- As per the first agreement- Ardelyx to receive $10M for research and is eligible to receive ~10.5M upfront and up to $500M as development & commercialization milestone and will execute research in collaboration with Kyowa Kirin for only two targets
- Following the end of the research period- Kyowa Kirin to get an option to license any candidates for the development & commercialization in selected territories. Ardelyx will receive $20M as equity investment from Kyowa Kirin for its 2-873-563 shares at $6.96/share- under the second agreement
- In Nov’2017- Ardelyx and Kyowa Kirin collaborated to develop & commercialize Tenapanor for cardiorenal diseases- including hyperphosphatemia in Japan which granted Kyowa Kirin an exclusive right to develop & commercialize Tenapanor in Japan
Click here to read full press release/ article | Ref: PRNewswire | Image: Cube Brush
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
